Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Manimozhiyan Arumugan"'
Autor:
Bjørn Stæhr Madsen, Jonel Trebicka, Maja Thiele, Mads Israelsen, Manimozhiyan Arumugan, Troels Havelund, Aleksander Krag
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-5 (2018)
Abstract Background Alcoholic liver disease is the leading cause of cirrhosis worldwide. Due to an increase in alcohol overuse, alcoholic liver disease has become an increased burden on health care systems. Abstinence from alcohol remains the corners
Externí odkaz:
https://doaj.org/article/66193979b8fb4e5f9afec2ead668c194
Autor:
BjøRn Madsen, Jonel Trebicka, Thiele, Maja, Israelsen, Mads, Manimozhiyan Arumugan, Havelund, Troels, Krag, Aleksander
SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 121 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=sygma_______::ea87b2ebd51230d52dea4e8deff44a28
https://doi.org/10.6084/m9.figshare.5927761
https://doi.org/10.6084/m9.figshare.5927761
Autor:
Mads Israelsen, Manimozhiyan Arumugan, Maja Thiele, Jonel Trebicka, Aleksander Krag, Bjørn Stæhr Madsen, Troels Havelund
Publikováno v:
Madsen, B S, Trebicka, J, Thiele, M, Israelsen, M, Arumugan, M, Havelund, T & Krag, A 2018, ' Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease : study protocol for a randomized controlled trial ', Trials, vol. 19, 143, pp. 1-5 . https://doi.org/10.1186/s13063-018-2523-9
Trials
Madsen, B S, Trebicka, J, Thiele, M, Israelsen, M, Arumugan, M, Havelund, T & Krag, A 2018, ' Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease : Study protocol for a randomized controlled trial ', Trials, vol. 19, 143 . https://doi.org/10.1186/s13063-018-2523-9
Trials, Vol 19, Iss 1, Pp 1-5 (2018)
Trials
Madsen, B S, Trebicka, J, Thiele, M, Israelsen, M, Arumugan, M, Havelund, T & Krag, A 2018, ' Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease : Study protocol for a randomized controlled trial ', Trials, vol. 19, 143 . https://doi.org/10.1186/s13063-018-2523-9
Trials, Vol 19, Iss 1, Pp 1-5 (2018)
Background Alcoholic liver disease is the leading cause of cirrhosis worldwide. Due to an increase in alcohol overuse, alcoholic liver disease has become an increased burden on health care systems. Abstinence from alcohol remains the cornerstone of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6267f3d43f6a387ba268287dad08ce11
https://curis.ku.dk/ws/files/204462132/Trials_document.pdf
https://curis.ku.dk/ws/files/204462132/Trials_document.pdf
Autor:
BjøRn Madsen, Jonel Trebicka, Thiele, Maja, Israelsen, Mads, Manimozhiyan Arumugan, Havelund, Troels, Krag, Aleksander
SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 121 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea87b2ebd51230d52dea4e8deff44a28
Autor:
BjøRn Madsen, Jonel Trebicka, Thiele, Maja, Israelsen, Mads, Manimozhiyan Arumugan, Havelund, Troels, Krag, Aleksander
SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 121 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d453466d3c74b4a7d900989eda2acf9